<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02155101</url>
  </required_header>
  <id_info>
    <org_study_id>ChantalIRCB</org_study_id>
    <nct_id>NCT02155101</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS</brief_title>
  <acronym>MANET</acronym>
  <official_title>Monotherapy in Africa: Evaluation of New Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Pharmaceutica</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chantal Biya International Reference Centre for Research on Prevention and Management of HIV/AIDS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yaounde Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Liverpool</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pilot study is to assess the feasibility, efficacy and safety of
      Darunavir/ritonavir 800/100 mg once daily (DRV/r) monotherapy as a switch-maintenance
      strategy for patients receiving second-line ART at Yaoundé Central Hospital in Cameroon.
      HIV-infected adults receiving second-line antiretroviral therapy (ART) for ≥3 months with 2
      nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus either lopinavir/ritonavir
      (LPV/r) or atazanavir/ritonavir (ATV/r) will undergo plasma HIV-1 RNA (&quot;viral&quot;) load testing.
      Those with a viral load below 50 copies/ml (&lt;50 cps/ml) will undergo a repeat test ideally
      4-6 weeks later (allowed up to 12 weeks); if the viral load is confirmed as &lt;50 cps/ml the
      patient will be invited to join the randomised phase of the study. Patients (n=150) will be
      randomised 1:2 to either continue the current triple ART regimen (n=50) or switch to DRV/r
      monotherapy (n=100). The primary end-point will be viral load suppression &lt;400 cps/ml at week
      24; secondary end-points will be viral load suppression &lt;50 cps/ml at week 12 and week 24,
      safety, tolerability, and emergence of protease inhibitor (PI) drug-resistance. Patients will
      continue observational follow-up depending on the treatment arm they are randomized to. After
      week 48, patients will return to local standard of care. Pharmacokinetics (PK) and
      pharmacogenomics sub-study to correlate plasma concentrations of DRV to outcomes, HIV-1 drug
      resistance testing sub study to detect mutants archived at the time of first-line ART failure
      and measuring HIV DNA load will be performed, as well as a cost-effectiveness analysis will
      test the hypothesis that savings can be achieved by switching to DRV/r monotherapy without
      affecting quality of care. The primary virological objective is to evaluate efficacy in terms
      of the percentage of subjects who have plasma HIV-1 RNA levels &lt;400 cps/ml after 24 weeks of
      follow-up following a switch to DRV/r monotherapy versus continuing triple therapy containing
      2 NRTIs + LPV/r (or ATV/r) (FDA Snapshot method).

      Study hypothesis:

      we propose that maintenance therapy with DRV/r monotherapy is a feasible, effective and safe
      treatment option for patients receiving second-line ART in Yaoundé.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV-1 RNA Viral Load</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percentage of subjects who have plasma HIV-1 RNA levels &lt;400 cps/ml after 24 weeks of follow-up following a switch to DRV/r monotherapy versus continuing triple therapy containing 2 NRTIs + LPV/r (or ATV/r) (FDA Snapshot method). The FDA 'Snapshot' algorithm evaluates HIV RNA response using only the results at the week 24 time-point which also means that rebound at earlier time-points are not classified as treatment failure, unless it lead to discontinuation prior to the week 48.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV-1 RNA Viral Load</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of subjects who have plasma HIV-1 RNA levels &lt;50 cps/ml after 12 weeks of follow-up following a switch to DRV/r monotherapy versus continuing triple therapy containing 2 NRTIs + LPV/r (or ATV/r), using the FDA &quot;Time to Loss of Virologic Response&quot; method. The FDA 'Snapshot' algorithm evaluates HIV RNA response using only the results at the week 12 time-point which also means that rebound at earlier time-points are not classified as treatment failure, unless it lead to discontinuation prior to the week 48.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HIV-1 RNA Viral Load</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percentage of subjects who have plasma HIV-1 RNA levels &lt;50 cps/ml after 24 weeks of follow-up following a switch to DRV/r monotherapy versus continuing triple therapy containing 2 NRTIs + LPV/r (or ATV/r), using the FDA &quot;Time to Loss of Virologic Response&quot; method. The FDA 'Snapshot' algorithm evaluates HIV RNA response using only the results at the week 24 time-point which also means that rebound at earlier time-points are not classified as treatment failure, unless it lead to discontinuation prior to the week 48.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>ART with 2 NRTIs plus LPV/r (or ATV/r)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus either lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Darunavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage form: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with &quot;400 mg&quot; on one side and TMC on the other side.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <description>Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side.</description>
    <arm_group_label>Darunavir</arm_group_label>
    <other_name>PREZISTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ART with 2 NRTIs plus LPV/r (or ATV/r)</intervention_name>
    <description>Patients on second line antiretroviral therapy take 2 NRTIs and either protease inhibitor lopinavir/ritonavir or atazanavir/ritonavir.</description>
    <arm_group_label>ART with 2 NRTIs plus LPV/r (or ATV/r)</arm_group_label>
    <other_name>NRTI, lopinavir/ritonavir (LPV/r), atazanavir/ritonavir (ATV/r)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with documented HIV-1 infection.

          2. Male or female aged &gt; 21 years old.

          3. Subjects receiving ART with 2 NRTIs + LPV/r (or ATV/r) for at least 3 months at the
             time of Screening 1.

          4. Nadir T lymphocyte cluster of differentiation 4 (CD4) &gt;100 cells/mm3

          5. Plasma HIV-1 RNA &lt;50 copies/ml at Screening 1 confirmed ideally 4-6 weeks later at
             Screening 2 (two results must be documented; a first result obtained up to 12 weeks
             earlier will be accepted).

          6. Subjects can comply with the protocol requirements. In particular, subjects should be
             willing to be followed up at least until week 24 (discontinuation prior to week 24)
             and for the DRV/r arm up to week 48 (discontinuation after week 24) even if they
             discontinue randomized treatment.

          7. Subjects who have voluntarily signed and dated the consent form.

        Exclusion Criteria:

          1. Clinical or laboratory evidence of significantly decreased hepatic function or
             decompensation, irrespective of liver enzyme levels (liver insufficiency).

          2. Co-infection with hepatitis B (HBsAg positive).

          3. Grade 3 or 4 laboratory abnormality as defined by AIDS, including haemoglobin ≤8mg/dL;
             platelets ≤50 000/mm3; estimated creatinine clearance ≤60ml/ minute, aspartate
             aminotransferase; alanine aminotransferase and alkaline phosphatase &gt;3 times the upper
             limit of normal; and total bilirubin &gt;2.5 times the upper limit of normal; with the
             following exceptions unless clinical assessment foresees an immediate health risk to
             the subject:

               -  Pre-existing diabetes or asymptomatic glucose grade 3 or 4 elevations.

               -  Asymptomatic triglyceride or cholesterol elevations of grade 3 or 4.

          4. Presence of any currently active AIDS defining illness (Category C conditions
             according to the Centers for Disease Control Classification System for HIV Infection
             1993) with the following exceptions:

               -  Stable cutaneous Kaposi's Sarcoma (i.e., no internal organ involvement other than
                  oral lesions) that is unlikely to require any form of systemic therapy during the
                  study.

               -  Wasting syndrome due to HIV infection. Note: An AIDS defining illness that is not
                  clinically stabilized for at least 30 days will be considered as currently
                  active.

          5. Pregnant or breastfeeding women.

          6. Active substance abuse, including alcohol or recreational drugs.

          7. Any clinically significant disease (e.g., tuberculosis, cardiac dysfunction,
             pancreatitis, acute viral infections) or life threatening disease in the previous 14
             days, or findings during screening of medical history or physical examination that, in
             the investigator's opinion, would compromise the subject's safety or outcome of the
             study.

          8. Any medical or psychiatric condition which, in the opinion of the investigator, could
             compromise the subject's safety or adherence to the trial protocol.

          9. Previously demonstrated clinically allergy or hypersensitivity to any of the
             excipients of the investigational medication (DRV).

             Note: DRV is a sulfonamide. Subjects who have previously experienced a sulfonamide
             allergy will be allowed to enter the trial. To date, no potential for cross
             sensitivity between drugs in the sulfonamide class and DRV has been identified in
             subjects participating in phase II trials.

         10. Participation in any other clinical trials that involve administration of
             antiretrovirals or other drugs within the last 4 weeks and during the participation in
             this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Maria Geretti, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Liverpool</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yaounde Central Hospital</name>
      <address>
        <city>Yaounde</city>
        <state>Centre</state>
        <zip>5777</zip>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cameroon</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 2, 2014</study_first_submitted>
  <study_first_submitted_qc>June 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2014</study_first_posted>
  <results_first_submitted>June 8, 2019</results_first_submitted>
  <results_first_submitted_qc>August 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 4, 2019</results_first_posted>
  <last_update_submitted>August 30, 2019</last_update_submitted>
  <last_update_submitted_qc>August 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liverpool</investigator_affiliation>
    <investigator_full_name>Anna Maria Geretti</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <keyword>Darunavir</keyword>
  <keyword>HIV-1 RNA level</keyword>
  <keyword>Cameroon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Darunavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ART With 2 NRTIs Plus LPV/r (or ATV/r)</title>
          <description>2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus either lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r).
ART with 2 NRTIs plus LPV/r (or ATV/r): Patients on second line antiretroviral therapy take 2 NRTIs and either protease inhibitor lopinavir/ritonavir or atazanavir/ritonavir.</description>
        </group>
        <group group_id="P2">
          <title>Darunavir</title>
          <description>Dosage form: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with &quot;400 mg&quot; on one side and TMC on the other side.
Darunavir: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ART With 2 NRTIs Plus LPV/r (or ATV/r)</title>
          <description>2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus either lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r).
ART with 2 NRTIs plus LPV/r (or ATV/r): Patients on second line antiretroviral therapy take 2 NRTIs and either protease inhibitor lopinavir/ritonavir or atazanavir/ritonavir.</description>
        </group>
        <group group_id="B2">
          <title>Darunavir</title>
          <description>Dosage form: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with &quot;400 mg&quot; on one side and TMC on the other side.
Darunavir: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="81"/>
            <count group_id="B3" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="38" upper_limit="51"/>
                    <measurement group_id="B2" value="45" lower_limit="37" upper_limit="52"/>
                    <measurement group_id="B3" value="45" lower_limit="38" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Cameroon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.0" lower_limit="22.5" upper_limit="29.2"/>
                    <measurement group_id="B2" value="25.4" lower_limit="21.8" upper_limit="28.4"/>
                    <measurement group_id="B3" value="25.5" lower_limit="22.1" upper_limit="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Haemoglobin</title>
          <units>g/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.4" lower_limit="11.6" upper_limit="13.5"/>
                    <measurement group_id="B2" value="12.3" lower_limit="11.6" upper_limit="13.2"/>
                    <measurement group_id="B3" value="12.3" lower_limit="11.6" upper_limit="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated glomerular filtration rate &gt;90</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since HIV diagnosis</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.0" lower_limit="5.5" upper_limit="9.8"/>
                    <measurement group_id="B2" value="8.8" lower_limit="5.9" upper_limit="11.1"/>
                    <measurement group_id="B3" value="8.5" lower_limit="5.8" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 cell count</title>
          <units>cells/mm3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="536" lower_limit="394" upper_limit="687"/>
                    <measurement group_id="B2" value="466" lower_limit="341" upper_limit="615"/>
                    <measurement group_id="B3" value="467" lower_limit="341" upper_limit="618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of previous AIDS defining diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-1 DNA</title>
          <units>log10 copies/106 PBMC</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.7" lower_limit="2.2" upper_limit="2.9"/>
                    <measurement group_id="B2" value="2.9" lower_limit="2.5" upper_limit="3.3"/>
                    <measurement group_id="B3" value="2.9" lower_limit="2.4" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration on antiretroviral therapy(ART)</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.9" lower_limit="4.9" upper_limit="9.2"/>
                    <measurement group_id="B2" value="7.6" lower_limit="5.3" upper_limit="9.8"/>
                    <measurement group_id="B3" value="7.5" lower_limit="5.3" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration on protease inhibitor based ART</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.1" lower_limit="1.5" upper_limit="4.9"/>
                    <measurement group_id="B2" value="3.2" lower_limit="1.3" upper_limit="5.8"/>
                    <measurement group_id="B3" value="3.1" lower_limit="1.3" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ART regimen at baseline</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Tenofovir/lamivudine + lopinavir/ritonavir</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abacavir + didanosine + lopinavir/ritonavir</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Zidovudine/lamivudine + lopinavir/ritonavir</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Tenofovir/lamivudine + atazanavir/ritonavir</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Tenofovir + abacavir + lopinavir/ritonavir</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HIV-1 RNA Viral Load</title>
        <description>Percentage of subjects who have plasma HIV-1 RNA levels &lt;400 cps/ml after 24 weeks of follow-up following a switch to DRV/r monotherapy versus continuing triple therapy containing 2 NRTIs + LPV/r (or ATV/r) (FDA Snapshot method). The FDA 'Snapshot' algorithm evaluates HIV RNA response using only the results at the week 24 time-point which also means that rebound at earlier time-points are not classified as treatment failure, unless it lead to discontinuation prior to the week 48.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ART With 2 NRTIs Plus LPV/r (or ATV/r)</title>
            <description>2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus either lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r).
ART with 2 NRTIs plus LPV/r (or ATV/r): Patients on second line antiretroviral therapy take 2 NRTIs and either protease inhibitor lopinavir/ritonavir or atazanavir/ritonavir.</description>
          </group>
          <group group_id="O2">
            <title>Darunavir</title>
            <description>Dosage form: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with &quot;400 mg&quot; on one side and TMC on the other side.
Darunavir: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side.</description>
          </group>
        </group_list>
        <measure>
          <title>HIV-1 RNA Viral Load</title>
          <description>Percentage of subjects who have plasma HIV-1 RNA levels &lt;400 cps/ml after 24 weeks of follow-up following a switch to DRV/r monotherapy versus continuing triple therapy containing 2 NRTIs + LPV/r (or ATV/r) (FDA Snapshot method). The FDA 'Snapshot' algorithm evaluates HIV RNA response using only the results at the week 24 time-point which also means that rebound at earlier time-points are not classified as treatment failure, unless it lead to discontinuation prior to the week 48.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV-1 RNA Viral Load</title>
        <description>Percentage of subjects who have plasma HIV-1 RNA levels &lt;50 cps/ml after 12 weeks of follow-up following a switch to DRV/r monotherapy versus continuing triple therapy containing 2 NRTIs + LPV/r (or ATV/r), using the FDA &quot;Time to Loss of Virologic Response&quot; method. The FDA 'Snapshot' algorithm evaluates HIV RNA response using only the results at the week 12 time-point which also means that rebound at earlier time-points are not classified as treatment failure, unless it lead to discontinuation prior to the week 48.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ART With 2 NRTIs Plus LPV/r (or ATV/r)</title>
            <description>2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus either lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r).
ART with 2 NRTIs plus LPV/r (or ATV/r): Patients on second line antiretroviral therapy take 2 NRTIs and either protease inhibitor lopinavir/ritonavir or atazanavir/ritonavir.</description>
          </group>
          <group group_id="O2">
            <title>Darunavir</title>
            <description>Dosage form: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with &quot;400 mg&quot; on one side and TMC on the other side.
Darunavir: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side.</description>
          </group>
        </group_list>
        <measure>
          <title>HIV-1 RNA Viral Load</title>
          <description>Percentage of subjects who have plasma HIV-1 RNA levels &lt;50 cps/ml after 12 weeks of follow-up following a switch to DRV/r monotherapy versus continuing triple therapy containing 2 NRTIs + LPV/r (or ATV/r), using the FDA &quot;Time to Loss of Virologic Response&quot; method. The FDA 'Snapshot' algorithm evaluates HIV RNA response using only the results at the week 12 time-point which also means that rebound at earlier time-points are not classified as treatment failure, unless it lead to discontinuation prior to the week 48.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>HIV-1 RNA Viral Load</title>
        <description>Percentage of subjects who have plasma HIV-1 RNA levels &lt;50 cps/ml after 24 weeks of follow-up following a switch to DRV/r monotherapy versus continuing triple therapy containing 2 NRTIs + LPV/r (or ATV/r), using the FDA &quot;Time to Loss of Virologic Response&quot; method. The FDA 'Snapshot' algorithm evaluates HIV RNA response using only the results at the week 24 time-point which also means that rebound at earlier time-points are not classified as treatment failure, unless it lead to discontinuation prior to the week 48.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ART With 2 NRTIs Plus LPV/r (or ATV/r)</title>
            <description>2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus either lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r).
ART with 2 NRTIs plus LPV/r (or ATV/r): Patients on second line antiretroviral therapy take 2 NRTIs and either protease inhibitor lopinavir/ritonavir or atazanavir/ritonavir.</description>
          </group>
          <group group_id="O2">
            <title>Darunavir</title>
            <description>Dosage form: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with &quot;400 mg&quot; on one side and TMC on the other side.
Darunavir: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side.</description>
          </group>
        </group_list>
        <measure>
          <title>HIV-1 RNA Viral Load</title>
          <description>Percentage of subjects who have plasma HIV-1 RNA levels &lt;50 cps/ml after 24 weeks of follow-up following a switch to DRV/r monotherapy versus continuing triple therapy containing 2 NRTIs + LPV/r (or ATV/r), using the FDA &quot;Time to Loss of Virologic Response&quot; method. The FDA 'Snapshot' algorithm evaluates HIV RNA response using only the results at the week 24 time-point which also means that rebound at earlier time-points are not classified as treatment failure, unless it lead to discontinuation prior to the week 48.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected over the 48 week study period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ART With 2 NRTIs Plus LPV/r (or ATV/r)</title>
          <description>2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus either lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r).
ART with 2 NRTIs plus LPV/r (or ATV/r): Patients on second line antiretroviral therapy take 2 NRTIs and either protease inhibitor lopinavir/ritonavir or atazanavir/ritonavir.</description>
        </group>
        <group group_id="E2">
          <title>Darunavir</title>
          <description>Dosage form: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with &quot;400 mg&quot; on one side and TMC on the other side.
Darunavir: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>acute anxiety, hospitalisation, resolved</sub_title>
                <counts group_id="E1" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>malaria, progressive anaemia, hospitalisation, transfusion reaction, death</sub_title>
                <counts group_id="E1" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Car accident, hospitalisation, resolved;</sub_title>
                <counts group_id="E1" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Acute febrile illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute hepatitis B</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pulmonary TB</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Anna Maria Geretti</name_or_title>
      <organization>University of Liverpool</organization>
      <phone>+44(0)151 795 9625</phone>
      <email>Geretti@liverpool.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

